Life Sciences

Life Sciences

In a constantly changing and challenging environment, the first rate expertise and experience of our team will help propel your life science company to success.

We can provide your company with the specialist knowledge needed to find solutions to key life science industry issues. We are a partner you can rely on in assignments focusing on, for example:

We have solid experience of handling assignments for Finnish and international pharmaceutical companies, health service providers as well as biotech and food industry companies. In international assignments we can provide you with in-depth insight into the Finnish legal environment and practical solutions for business needs.

Our excellence has been noted in ratings by Best Lawyers, Intellectual Asset Management (IAM), Chambers Global, Chambers Europe, Who’s Who Legal and PLC.

Latest references

Mérieux Equity Partners – Acquisition of Labquality
We acted as the legal and ESG advisor to Mérieux Equity Partners on the acquisition of a majority stake in Labquality through a leveraged buyout by its buyout fund, Mérieux Participations 4. Existing shareholders of Labquality, including Cor Group and the management, will reinvest a portion of their proceeds into the company in connection with the transaction. Headquartered in Helsinki, Finland, Labquality is a Nordic player specialized in EQA, CRO activities and regulatory affairs, with a strong local presence in Central and Eastern Europe. The company provides a comprehensive array of services for the healthcare, medical technology, and pharmaceutical industries. The company, employing over 120 professionals and supported by a network of more than 150 external experts and consultants across its offices in Finland, Germany, and Poland, serves a diverse clientele of over 8,000 customers, including major pharmaceutical companies in over 60 countries. Mérieux Equity Partners (MxEP) is an AMF-accredited management company dedicated to equity investments in the Healthcare and Nutrition sectors. MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. The transaction will enable Labquality to pursue its buy & build strategy in Europe to accelerate its CRO activities while continuing strong and recurring growth in the EQA segment. Labquality will benefit from MxEP’s sector expertise and financial resources to achieve its ambition of becoming a leading European CRO and EQA platform, with fully integrated regulatory consulting capabilities to serve major customers across Europe.
Case published 4.12.2023
Voisin Consulting Life Sciences (VCLS) – Acquisition of MedEngine
We advised Voisin Consulting Life Sciences (VCLS) on the acquisition of MedEngine, a leading medical science agency in the Nordics. MedEngine is a digitally minded, premium service provider for the pharmaceutical industry, built upon extensive academic expertise and years of experience in the industry. Founded in 2014, MedEngine has a strong presence across the Nordic countries with offices in Helsinki (Finland), Copenhagen (Denmark), and Stockholm (Sweden). Founded in 1997, VCLS provides end-to-end HealthTech solutions to support biotechnology, pharmaceutical and MedTech manufacturers throughout their product development. With offices in the US, France, UK, Switzerland, Denmark, Madagascar, India, and China, VCLS serves a broad range of developers and investors in HealthTech.
Case published 7.11.2023
Biovian – Manufacturing facility project
We acted as advisor to Biovian in a EUR 50 million manufacturing facility project in Turku, Finland. The new facility to be constructed in connection with the project will cover an area of 6,400 sqm and house cutting-edge equipment and advanced technologies to support the development, manufacturing, and testing of ATMP (Advanced Therapy Medicinal Products). It will also feature dedicated Class A to D cleanroom areas for bulk drug substances as well as final drug product manufacture. The construction project is expected to be completed in December 2024. Biovian is a globally operating GMP (Good Manufacturing Practice) contract development and manufacturing organisation (CDMO) of biopharmaceuticals, providing development and manufacturing services from early stage to finished product. Biovian is especially focusing on viral vector production, microbial production of recombinant proteins and GMP plasmid DNA.
Case published 30.8.2023
Inventure, Tesi and Presidio Ventures – Algorithmiq’s EUR 13.7 million series A funding round
We advised Inventure, Tesi (i.e. Finnish Industry Investment) and Presidio Ventures on the EUR 13.7 million series A funding round of Algorithmiq, a Helsinki-based growth company developing quantum computing algorithms and solutions for drug development and discovery. The round was led by Inventure, with participation from Tesi, Presidio Ventures, Thames Trust and existing investors. This latest round of investment will enable Algorithmiq to pursue its proof-of-concept work with pharmaceutical companies globally, dramatically reducing the time and cost of drug discovery and development, a process that typically takes around a decade and a billion dollars for a new drug to reach the market.  We advised the investors alongside Wilson Sonsini Goodrich & Rosati.
Case published 24.8.2023
All cases

Our team

Latest insights

Article published 2.5.2024 – Private Equity & Venture Capital Strong momentum in life sciences and health tech industry: Castrén & Snellman sees a significant uptick in deal-making 
Karlo Siirala
Hanna Paloheimo
Sakari Lukinmaa
Tero Tuomisto
Antti Kaakkola

Karlo Siirala, Hanna Paloheimo, Sakari Lukinmaa, Tero Tuomisto & Antti Kaakkola

 Article published 5.9.2022 – Data & Technology The EU is currently trying to decide what kind of intelligent systems we will use in the future
Eija Warma-Lehtinen
Sakari Salonen

Eija Warma-Lehtinen & Sakari Salonen

 Article published 2.10.2024 – Banking & Finance Sustainable finance is vital for achieving the objectives of the green transition
Minna Korhonen
Lia Heasman

Minna Korhonen & Lia Heasman

 Article published 16.9.2024 – Banking & Finance Private credit – an alternative to bank financing
Tero Tuomisto
Minna Korhonen
Jenny Shahnovskij

Tero Tuomisto, Minna Korhonen & Jenny Shahnovskij
Insights